Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): A randomised non-inferiority trial
The Lancet Jun 27, 2019
Ross JDC, et al. – Via performing a multicenter, parallel-group, pragmatic, randomized, non-inferiority trial that included a cohort of 1,762 patients, researchers determined the fruitfulness of gentamicin as an alternative to ceftriaxone (both combined with azithromycin) in the treatment of gonorrhea. The investigators noted that a single dose of gentamicin 240 mg was non-inferior to a single dose of ceftriaxone 500 mg for the treatment of gonorrhea, when both drugs were combined with a 1-g dose of oral azithromycin. However, the pain severity at the injection site was greater for gentamicin, and the side-effect statuses were similar between gentamicin and ceftriaxone group. Hence, as first-line treatment for gonorrhea, gentamicin was not observed as an appropriate drug; however, it may have clinical utility for patients with isolated genital infection or for patients who are allergic or intolerant to ceftriaxone or harbor a ceftriaxone-resistant isolate.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries